Johnson & Johnson Covid-19 vaccine is 66% effective in global trial, but 85% effective against severe disease, company says
(CNN) Johnson & Johnson’s Covid-19 single-shot vaccine was shown to be 66% effective in preventing moderate and severe disease in a global Phase 3 trial, but 85% efficacy against severe disease, the company announced Friday.
The vaccine was 72% effective against moderate and severe disease in the US, the company said.
It’s a striking difference from vaccines from Pfizer/BioNTech and Moderna, and it may give pause to people uncertain about which vaccine to get or when they can get one.
The vaccines already on the market in the US are about 95% effective overall against symptomatic Covid-19, with perhaps even higher efficacy against severe cases.
But experts say the Johnson & Johnson vaccine will still be useful against the pandemic in the United States and around the world.
“Among all participants from different geographies and including those infected with an emerging viral variant, Janssen’s COVID-19 vaccine candidate was 66% effective overall at preventing the combined endpoints of moderate and severe COVID-19, 28 days after vaccination.
The onset of protection was observed as early as day 14,” the company said in a statement.
COPYRIGHT 2021 BY YAKTRINEWS. ALL RIGHTS RESERVED. THIS MATERIAL MAY NOT BE PUBLISHED, BROADCAST, REWRITTEN OR REDISTRIBUTED.